Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03250507 · ClinicalTrials.gov registry record · Phase 4

Mixture of Liposomal Bupivacaine and Bupivacaine for TAP Block for Open Hysterectomy

A Phase 4 study of Hysterectomy, sponsored by Henry Ford Health System.

Completed
Registry status
Phase 4
Development phase
90
Enrollment target
1
Study location

NCT03250507 is a Phase 4 study of Hysterectomy that has completed, run by Henry Ford Health System. The registered enrollment target is 90 participants, below the 128-participant average among 8 other Hysterectomy trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03250507, a Phase 4 study of Hysterectomy, has completed, sponsored by Henry Ford Health System.

COMPLETED
Registry status
Phase 4
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to evaluate the effectiveness of different formulations of bupivacaine infiltrated into the transversus abdominis plane (TAP) on post-operative pain management after open abdominal hysterectomy.

Conditions Studied

Interventions

  • DRUG Bupivacaine
  • DRUG Saline
  • DRUG Liposomal bupivacaine

Study Locations (1)

Michigan

  • Henry Ford Hospital - Detroit

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2017-03-13
Est. Completion 2019-01-30
Phase Phase 4

Sponsor

Henry Ford Health System

234 total trials

What the Registry Record Tells You About NCT03250507

The ClinicalTrials.gov registry entry for NCT03250507 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 8 other Hysterectomy trials with a reported enrollment target (30% lower). The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hysterectomy appearing as the primary indexed condition, and to 3 interventions - of which Bupivacaine is the first listed.

NCT03250507 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT03250507 about?

NCT03250507 is a clinical study titled "Mixture of Liposomal Bupivacaine and Bupivacaine for TAP Block for Open Hysterectomy". The goal of this study is to evaluate the effectiveness of different formulations of bupivacaine infiltrated into the transversus abdominis plane (TAP) on post-operative pain management after open abdominal hysterectomy.

What is the current status of trial NCT03250507?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2017-03-13. Estimated completion is 2019-01-30.

What conditions does trial NCT03250507 study?

This clinical trial studies the following conditions: Hysterectomy.

What interventions are being tested in trial NCT03250507?

The interventions under investigation include: Bupivacaine (DRUG), Saline (DRUG), Liposomal bupivacaine (DRUG).

Who is sponsoring clinical trial NCT03250507?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03250507 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hysterectomy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.